Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
Date:7/7/2009

products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1032 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
6. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
7. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
8. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
10. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
11. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... of building materials using light, developed by researchers at ... that are often considered the realm of science fiction, ... Although cloaked starships won,t be a reality for quite ... constructing materials with building blocks a few billionths of ... way that light flies through them, and works on ...
(Date:7/28/2014)... According to a new market research report published ... Joint) Market (By Technology - Stem Cell Therapy, ... Graft Substitutes, Osteoarticular Diseases, Allogeneic Products, Autogenic Products ... Growth, Trends and Forecast, 2013 - 2019" the ... valued at USD 2.6 billion in 2012 and ...
(Date:7/28/2014)... , July 28, 2014 ... report  "Microbial Identification Market by Products (Consumables, Instruments, Services), ... Beverages), End User (Detection, Characterization) - Global ... Microbial Identification Market is estimated at $896.5 ... reach $1,194.1 Million by 2019, growing at ...
(Date:7/28/2014)... 28, 2014 Appistry, Inc. , ... bring the power of genomics to next-generation medicine, announced ... Pipeline Challenge . , Two Appistry staff will ... National Center for Genome Resources, and Mr. Neil Miller, ... of Kansas City. Rounding out the panel are Appistry’s ...
Breaking Biology Technology:Building 'invisible' materials with light 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2
... researchers have identified a gene that is specifically responsible ... lead to stem cell therapies to treat brain injuries ... Edwin Monuki, doctoral student Karla Hirokawa and their colleagues ... Developmental & Cell Biology found that a gene called ...
... Jan. 17 NEXCORE Technology,Inc, a world-class original ... the intellectual property rights for the,development of a ... new system provides significantly greater control over the,inflow/outflow ... on the system are held by Drs. Atul ...
... Program Under Development to Improve Outcomes of Coronary ... Grafting (CABG) and Cardiac Valve Surgeries, VANCOUVER, ... -,Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ... that they have entered into an,exclusive licensing agreement ...
Cached Biology Technology:Discovery of 'creator' gene for cerebral cortex points to potential stem cell treatments 2NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System 2Angiotech and Symphony Medical Announce Licensing Agreement 2Angiotech and Symphony Medical Announce Licensing Agreement 3Angiotech and Symphony Medical Announce Licensing Agreement 4Angiotech and Symphony Medical Announce Licensing Agreement 5Angiotech and Symphony Medical Announce Licensing Agreement 6
(Date:7/28/2014)... suggest two ways to effectively address the problem that birth ... compared to women of a normal body mass index. , ... as the population has increased in weight, concern has grown ... have consistently found that obesity has a negative impact on ... how well the pill prevents pregnancy. , "Birth ...
(Date:7/28/2014)... (July 28, 2014) Rice University researchers are ... of varying flexibility that can be used as microscale ... proof that "bead-spring" polymers, introduced as theory in the ... as required and should be of interest to materials ... The work led by Rice chemical and biomolecular engineer ...
(Date:7/28/2014)... body,s natural virus killers to prevent and treat HIV ... strong inflammatory response these molecules can arouse as they ... by scientists at the Weizmann Institute and the National ... activity of these molecules interferons around the ... course of the disease. Their research appeared in ...
Breaking Biology News(10 mins):Strategies identified to improve oral contraceptive success with obese women 2Seeing is bead-lieving 2Interfering with interferon 2
... syndrome has focused on the DYRK1A gene. The superexpression ... to Mr Garikoitz Azkona. In his PhD thesis, ... role of DYRK1A , Mr Azkona argues that this ... that persons with Down,s syndrome have regarding visual-spatial memory. ...
... 2010 2009 estimates projected that in the United States ... and 14,600 women would die of the disease. Often ... and a relatively low 5-year survival rate of about 45%. ... in the March 2010 issue of the Journal of ...
... treatment for cancer might come from fish says a new ... the FASEB Journal ( http://www.fasebj.org ). In the ... or "DHA," and its derivatives in the body kill neuroblastoma ... a wide range of cancers, including neuroblastoma, medulloblastoma, colon, breast, ...
Cached Biology News:DYRK1A gene may be 1 of most influential factors in Down syndrome 2Dietary factors influence ovarian cancer survival rates 2
... adsorption and clarification reagent; Ideal for ... of antibodies, proteins, nucleic acids, & ... cross-reactivity, and improves downstream processing; Utilizes ... non-ionic adsorbent supplied as a suspension ...
AC input: 230 V...
... The lyophilization stabilizer is designed ... process and for long-term storage. ... toxic ingredients. It is a ... pH 7.2, and is superior to ...
... The lyophilization stabilizer is designed to ... and for long-term storage. There ... ingredients. It is a convenient ... 7.2, and is superior to other ...
Biology Products: